Pharmarise Holdings Corporation (TYO:2796)
Japan · Delayed Price · Currency is JPY 528.00
+2.00 (0.38%)
May 8, 2026, 3:30 PM JST
Pharmarise Holdings Income Statement
Financials in millions JPY. Fiscal year is June - May.
Millions JPY. Fiscal year is Jun - May.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Feb '26 Feb 28, 2026 | May '25 May 31, 2025 | May '24 May 31, 2024 | May '23 May 31, 2023 | May '22 May 31, 2022 | May '21 May 31, 2021 |
| 67,485 | 63,508 | 54,466 | 52,030 | 51,608 | 52,324 | |
Revenue Growth (YoY) | 11.85% | 16.60% | 4.68% | 0.82% | -1.37% | 2.54% |
Cost of Revenue | 58,152 | 54,542 | 46,017 | 43,896 | 43,491 | 44,256 |
Gross Profit | 9,333 | 8,966 | 8,449 | 8,134 | 8,117 | 8,068 |
Selling, General & Admin | 4,731 | 4,860 | 4,371 | 3,728 | 3,525 | 3,659 |
Amortization of Goodwill & Intangibles | 763 | 763 | 557 | 635 | 700 | 738 |
Other Operating Expenses | 3,048 | 3,048 | 2,605 | 2,332 | 2,371 | 2,417 |
Operating Expenses | 8,542 | 8,671 | 7,533 | 6,695 | 6,596 | 6,821 |
Operating Income | 791 | 295 | 916 | 1,439 | 1,521 | 1,247 |
Interest Expense | -251 | -178 | -66 | -55 | -65 | -75 |
Interest & Investment Income | 13 | 10 | 1 | 2 | 2 | 2 |
Other Non Operating Income (Expenses) | 3 | -10 | -19 | 44 | 58 | 54 |
EBT Excluding Unusual Items | 556 | 117 | 832 | 1,430 | 1,516 | 1,228 |
Gain (Loss) on Sale of Investments | 4 | 7 | 19 | 30 | - | -4 |
Gain (Loss) on Sale of Assets | 37 | 20 | -1 | -4 | 2 | 61 |
Asset Writedown | -238 | -258 | -296 | -393 | -218 | -51 |
Other Unusual Items | 151 | 124 | -411 | -14 | 21 | -32 |
Pretax Income | 474 | 10 | 143 | 1,049 | 1,321 | 1,202 |
Income Tax Expense | 589 | 390 | 485 | 702 | 864 | 782 |
Earnings From Continuing Operations | -115 | -380 | -342 | 347 | 457 | 420 |
Minority Interest in Earnings | 7 | 13 | -9 | -14 | -10 | 6 |
Net Income | -108 | -367 | -351 | 333 | 447 | 426 |
Net Income to Common | -108 | -367 | -351 | 333 | 447 | 426 |
Net Income Growth | - | - | - | -25.50% | 4.93% | -26.17% |
Shares Outstanding (Basic) | 12 | 11 | 11 | 9 | 9 | 9 |
Shares Outstanding (Diluted) | 12 | 11 | 11 | 12 | 12 | 12 |
Shares Change (YoY) | 1.58% | 7.58% | -15.61% | 0.59% | 0.20% | -1.03% |
EPS (Basic) | -9.46 | -32.42 | -33.35 | 35.42 | 47.90 | 45.78 |
EPS (Diluted) | -9.46 | -32.42 | -33.35 | 26.86 | 36.22 | 34.59 |
EPS Growth | - | - | - | -25.83% | 4.70% | -25.31% |
Free Cash Flow | - | 674 | 2,242 | 2,140 | 334 | 1,437 |
Free Cash Flow Per Share | - | 59.53 | 213.04 | 171.61 | 26.94 | 116.15 |
Dividend Per Share | 14.000 | 14.000 | 14.000 | 14.000 | 14.000 | 14.000 |
Gross Margin | - | 14.12% | 15.51% | 15.63% | 15.73% | 15.42% |
Operating Margin | 1.17% | 0.46% | 1.68% | 2.77% | 2.95% | 2.38% |
Profit Margin | -0.16% | -0.58% | -0.64% | 0.64% | 0.87% | 0.81% |
Free Cash Flow Margin | - | 1.06% | 4.12% | 4.11% | 0.65% | 2.75% |
EBITDA | 2,526 | 1,788 | 2,086 | 2,663 | 2,829 | 2,591 |
EBITDA Margin | - | 2.81% | 3.83% | 5.12% | 5.48% | 4.95% |
D&A For EBITDA | 1,735 | 1,493 | 1,170 | 1,224 | 1,308 | 1,344 |
EBIT | 791 | 295 | 916 | 1,439 | 1,521 | 1,247 |
EBIT Margin | - | 0.46% | 1.68% | 2.77% | 2.95% | 2.38% |
Effective Tax Rate | - | 3900.00% | 339.16% | 66.92% | 65.41% | 65.06% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.